AGN 3222 | 666175-74-2

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: AGN 3222
• 英文别名: 3-(3', 5'-dimethoxyphenyl)-3-(3"-N,N-dimethylamino-propyl)-4,4-dimethyl-2,6-dioxopiperidine；3-(3',5'-dimethoxyphenyl)-3-(3''-N,N-dimethylamino-propyl)-4,4-dimethyl-2,6-dioxopiperidine；3-(3,5-Dimethoxyphenyl)-3-[3-(dimethylamino)propyl]-4,4-dimethylpiperidine-2,6-dione
• CAS: 666175-74-2
• 化学式: C₂₀H₃₀N₂O₄
• 分子量: 362.469
• InChiKey: YOGIZNRHMDDKAA-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.4
• 重原子数：
  26
• 可旋转键数：
  7
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.6
• 拓扑面积：
  67.9
• 氢给体数：
  1
• 氢受体数：
  5

文献信息

• [EN] PIPERIDIN-2,6-DIONE PAMOATE SALTS AND THEIR USE FOR THE TREATMENT OF STRESS-RELATED AFFECTIVE DISORDERS<br/>[FR] PAMOATES DE PIPERIDINE-2,6-DIONE ET LEUR UTILISATION POUR LE TRAITEMENT DE TROUBLES AFFECTIFS EN LIAISON AVEC LE STRESS
  申请人：PRESTWICK PHARMACEUTICALS INC

  公开号：WO2004017970A1

  公开（公告）日：2004-03-04

  Novel pamoate salts of certain 3-phenyl-3-dimethylaminoalkyl-4,4dimethylpiperidin-2,6-diones (1) and pharmacologically acceptable solvates thereof are devoid of the weight loss and hepatocyte changes in the rat which limited to marginally effective levels the permitted clinical doses of the corresponding hydrochlorides in the treatment or prophylaxis of stress-related affective disorders such as anxiety, depression, migraine and sleep apnoea. The preferred pamoate salts are 3(3,5dimethoxyphenyl)-3-(3-dimethylaminopropyl)-4,4-dimethylpiperidine-2,6-dione pamoate and, especially, 3(3-methoxyphenyl)-3-(3-dimethylaminopropyl)-4,4-dimethylpiperidine2,6-dione pamoate.

  某些3-苯基-3-二甲基氨基烷基-4,4-二甲基哌啶-2,6-二酮（1）的帕莫酸盐及其药学上可接受的溶剂化物，在治疗或预防压力相关情感障碍，如焦虑、抑郁、偏头痛和睡眠呼吸暂停中，不会出现大鼠体重减轻和肝细胞变化，这限制了相应盐酸的允许临床剂量的边缘有效水平。首选的帕莫酸盐是3（3,5-二甲氧基苯基）-3-（3-二甲基氨丙基）-4,4-二甲基哌啶-2,6-二酮帕莫酸盐，尤其是3（3-甲氧基苯基）-3-（3-二甲基氨丙基）-4,4-二甲基哌啶-2,6-二酮帕莫酸盐。
• Use of dioxopiperidine derivatives in the treatment of anxiety, for the reduction of chronic abnormally high brain levels of serotonin or 5-hydroxy-indoleacetic acid, and in the treatment of bacterial or viral infections
  申请人：BRITISH TECHNOLOGY GROUP LIMITED

  公开号：EP0216555A2

  公开（公告）日：1987-04-01

  Phenyl-3-aminoalkyl-4-methyl-2,6-dioxopiperidines of the Formula I wherein: R1 represents methoxy, ethoxy or hydroxy, R2 represents methoxy, ethoxy. hydroxy or hydrogen; each R3 independently represents methyl or ethyl; R4 represents hydrogen or methyl; R5 represents hydrogen or methyl; and n represents 2 or 3, and a pharmacologically acceptable acid addition salt thereof (a) have anxiolytic activity, (b) antagonize the anxiogenic activity of benzodiazepine inverse agonists. (c) reducechronic abnormally high brain levels of serotonin or its metabolite 5-hydroxy-indoleacetic acid and (d) have antibacterial and antiviral activity. These activities are believed to be related to a reduction in serotonin turnover caused by blocking the depolarisation activation of tryptophan hydroxylase. Novel compositions comprise the compounds with a benzodiazepine agonist or benzodiazepine inverse agonist.

  式 I 的苯基-3-氨基烷基-4-甲基-2,6-二氧代哌啶类化合物 其中 R1 代表甲氧基、乙氧基或羟基、 R2 代表甲氧基、乙氧基、羟基或氢 每个 R3 独立地代表甲基或乙基 R4 代表氢或甲基 R5 代表氢或甲基；以及 n 代表 2 或 3、 及其药理上可接受的酸加成盐 (a) 具有抗焦虑活性，(b) 可拮抗苯并二氮杂卓反向激动剂的致焦虑活性。(c) 降低大脑中血清素或其代谢物 5-羟基吲哚乙酸的长期异常高水平；以及 (d) 具有抗菌和抗病毒活性。据信，这些活性与通过阻断色氨酸羟化酶的去极化活化而导致的血清素周转减少有关。新型组合物由这些化合物与苯并二氮杂卓激动剂或苯并二氮杂卓反向激动剂组成。
• Use of dioxopiperidine derivatives for the manufacture of topical medicaments as analgesics
  申请人：BRITISH TECHNOLOGY GROUP LIMITED

  公开号：EP0295836A2

  公开（公告）日：1988-12-21

  Phenyl-3-aminoalkyl-4-methyl-2,6-dioxopiperidines of the Formula I wherein:     R₁ represents hydrogen or C₁-C₄ alkyl;     n is 1 or 2;     R₂ represents hydrogen or methyl, provided that one R₂ is hydrogen when n is 2;     R₃ represents hydrogen or C₁-C₂ alkyl;     R₄ represents C₁-C₂ alkyl;     R₅ and R₆ independently represent hydrogen or methyl;     m is 0 to 3; and     each Y is in a meta or para position and independently represents hydroxy, C₁-C₂ alkoxy, C₁-C₂ alkyl, C₁-C₂ hydroxyalkyl, halogen, or trifluoromethyl, provided that hydroxy and alkoxy are not in the para position, or a pharmacologically acceptable acid addition salt thereof have analgesic activity. The compounds can be administered enterally, parenterally or topically. The topical compositions are novel. The presently preferred compound is 3-(3′methoxyphenyl)-3-(3˝-N,N-dimethylaminopropyl)­-4,4-dimethyl-2,6-dioxopiperidine (AGN 2979).

  式 I 的苯基-3-氨基烷基-4-甲基-2,6-二氧代哌啶类化合物 其中 R₁ 代表氢或 C₁-C₄ 烷基； n 为 1 或 2； R₂ 代表氢或甲基，但当 n 为 2 时，其中一个 R₂ 为氢； R₃ 代表氢或 C₁-C₂ 烷基； R₄ 代表 C₁-C₂ 烷基； R₅ 和 R₆ 各自代表氢或甲基； m为0至3；以及 每个 Y 位于元位或对位，独立地代表羟基、C₁-C₂烷氧基、C₁-C₂烷基、C₁-C₂羟基烷基、卤素或三氟甲基，但羟基和烷氧基不位于对位、 或其药理学上可接受的酸加成盐具有镇痛活性。这些化合物可经肠道、肠外或局部给药。外用组合物是新颖的。 目前优选的化合物是 3-(3′甲氧基苯基)-3-(3˝-N,N-二甲基氨基丙基)-4,4-二甲基-2,6-二氧代哌啶（AGN 2979）。
• Antipsychotic compositions containing dioxopiperidine derivatives
  申请人：BRITISH TECHNOLOGY GROUP LIMITED

  公开号：EP0298738A2

  公开（公告）日：1989-01-11

  Phenyl-3-aminoalkyl-4-methyl-2,6-dioxopiperidines of the Formula I wherein: R, represents hydrogen or C1-C4 alkyl; n is 1 or 2; R2 represents hydrogen or methyl, provided that one R2 is hydrogen when n is 2: R3 represents hydrogen or C1-C2 alkyl; R4. represents C1-C2 alkyl; Rs and R6 independently represent hydrogen or methyl; m is 0 to 3; and each Y is in a meta or para position and independently represents hydroxy, C1-C2 alkoxy, C1-C2 alkyl. C1-C2 hydroxyalkyl, halogen, or trifluoromethyl, provided that hydroxy and alkoxy are not in the para position, and pharmacologically acceptable salts thereof have antiposychotic activity without sedative side effects. They are particularly useful in the treatment of schizophrenia. The presently preferred compound is 3-(3'methoxyphenyl)-3-(3"-N,N-dimethylaminopropyl)-4,4-dimethyl-2,6-dioxopiperidine (AGN 2979).

  式 I 的苯基-3-氨基烷基-4-甲基-2,6-二氧代哌啶类化合物 其中 R，代表氢或 C1-C4 烷基； n 为 1 或 2； R2 代表氢或甲基，但当 n 为 2 时，其中一个 R2 为氢： R3 代表氢或 C1-C2 烷基； R4 代表 C1-C2 烷基； Rs 和 R6 各自代表氢或甲基； m 为 0 至 3；以及 每个 Y 位于元位或对位，独立地代表羟基、C1-C2 烷氧基、C1-C2 烷基、C1-C2 羟基烷基、C1-C2 烷氧基烷基、C1-C2 羟基烷基C1-C2羟基烷基、卤素或三氟甲基，但羟基和烷氧基不在对位，其药理上可接受的盐类具有抗osychotic活性，且无镇静副作用。 它们特别适用于治疗精神分裂症。 目前首选的化合物是 3-(3'甲氧基苯基)-3-(3"-N,N-二甲基氨基丙基)-4,4-二甲基-2,6-二氧代哌啶（AGN 2979）。
• Anti-anxiogenic compositions containing dioxopiperidine derivatives
  申请人：BRITISH TECHNOLOGY GROUP LIMITED

  公开号：EP0299680A2

  公开（公告）日：1989-01-18

  Phenyl-3-aminoalkyl-4-methyl-2,6-dioxopiperidines of the Formula I wherein:     R₁ represents hydrogen or C₁-C₄ alkyl;     n is 1 or 2;     R₂ represents hydrogen or methyl, provided that one R₂ is hydrogen when n is 2;     R₃ represents hydrogen or C₁-C₂ alkyl;     R₄ represents C₁-C₂ alkyl;     R₅ and R₆ independently represent hydrogen or methyl;     m is 0 to 3; and     each Y is in a meta or para position and independently represents hydroxy, C₁-C₂ alkoxy, C₁-C₂ alkyl, C₁-C₂ hydroxyalkyl, halogen, or trifluoromethyl, provided that hydroxy and alkoxy are not in the para position, and pharmacologically acceptable salts thereof antagonise anxiogenesis associated with withdrawal from addictive drugs, especially alcohol, cocaine and nicotine. The presently preferred compound is 3-(3′methoxyphenyl)-3-(3˝-N,N-dimethylaminopropyl) -4,4-dimethyl-2,6-dioxopiperidine (AGN 2979).

  式 I 的苯基-3-氨基烷基-4-甲基-2,6-二氧代哌啶类化合物 其中 R₁ 代表氢或 C₁-C₄ 烷基； n 为 1 或 2； R₂ 代表氢或甲基，但当 n 为 2 时，其中一个 R₂ 为氢； R₃ 代表氢或 C₁-C₂ 烷基； R₄ 代表 C₁-C₂ 烷基； R₅ 和 R₆ 各自代表氢或甲基； m为0至3；以及 每个 Y 位于偏位或对位，独立地代表羟基、C₁-C₂烷氧基、C₁-C₂烷基、C₁-C₂羟基烷基、卤素或三氟甲基，但羟基和烷氧基不位于对位、 及其药理学上可接受的盐类可拮抗与成瘾性药物（尤其是酒精、可卡因和尼古丁）戒断相关的焦虑生成。 目前优选的化合物是 3-(3′甲氧基苯基)-3-(3˝-N,N-二甲基氨基丙基)-4,4-二甲基-2,6-二氧代哌啶（AGN 2979）。